Madrigal Pharmaceuticals to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
June 05, 2024 08:00 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., June 05, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the Goldman Sachs 45th Annual Global...
CytoSorbents to Host its 2024 Virtual Annual Stockholders Meeting
June 05, 2024 07:00 ET
|
CytoSorbents
CytoSorbents to Host its 2024 Virtual Annual Stockholders Meeting
Abivax releases the results of its May 30, 2024 Ordinary and Extraordinary General Meeting
June 04, 2024 16:10 ET
|
Abivax
PARIS, France, June 4, 2024 – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the...
Quell Therapeutics Advances QEL-001, its Multi-modular Engineered CAR-Treg Cell Therapy, into Efficacy Cohort of LIBERATE Phase 1/2 Trial in Liver Transplant Patients
June 04, 2024 13:30 ET
|
Quell TX
Progress in the LIBERATE trial was presented at the American Transplant Congress today London, UK– June 4, 2024 – Quell Therapeutics Ltd (“Quell”), a leader in developing engineered...
23andMe and the Colorectal Cancer Alliance Collaborate to Help Advance Colorectal Cancer Research in the Black Community
June 04, 2024 07:00 ET
|
23andMe, Inc.
SUNNYVALE, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, and the Colorectal Cancer Alliance...
ExeVir Bio Announces Exceptional Virus Neutralization Potency of its Variant-proof XVR013m Antibody Against the SARS-CoV-2 Variant JN.1
June 04, 2024 03:00 ET
|
ExeVir Bio
GHENT, Belgium, June 04, 2024 (GLOBE NEWSWIRE) -- ExeVir Bio, a biotech company developing robust heavy chain-only antibody therapies for broad protection against infectious diseases, today...
23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, targeting CD200R1, at the 2024 ASCO Annual Meeting
June 03, 2024 08:00 ET
|
23andMe, Inc.
– 23ME-00610 monotherapy demonstrates preliminary evidence of clinical benefit, including one confirmed partial response – 23ME-00610 monotherapy continues to demonstrate acceptable safety and...
Kraig Biocraft Laboratories Announces BAM-1 Spider Silk Hybrids are in Production
June 03, 2024 07:05 ET
|
Kraig Biocraft Laboratories
Kraig Labs (OTCQB: KBLB) is now in production with its BAM-1 spider silk hybrids, following the resounding successes of its spring production trials
atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference
May 31, 2024 07:00 ET
|
atai Life Sciences
NEW YORK and BERLIN, May 31, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental...
Celcuity Announces Pricing of Underwritten Common Stock Offering
May 30, 2024 07:36 ET
|
Celcuity Inc.
MINNEAPOLIS, May 30, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the...